Page last updated: 2024-12-05

5-methoxyindole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-Methoxyindole is a heterocyclic aromatic compound. It is a key precursor for the synthesis of various indole-based pharmaceuticals and natural products. It is known to exhibit biological activities, including anti-inflammatory, antimicrobial, and antioxidant properties. Its synthesis is typically achieved through the Fischer indole synthesis or by the reaction of 5-methoxyphenylhydrazine with a suitable ketone or aldehyde. 5-Methoxyindole has garnered interest for its potential therapeutic applications and its role in the biosynthesis of natural products. It is extensively studied for its pharmacological effects and its potential to modulate various biological pathways.'

5-methoxyindole: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID13872
CHEMBL ID280311
CHEBI ID167807
SCHEMBL ID74720
MeSH IDM0468350

Synonyms (60)

Synonym
unii-dqm3as43pq
dqm3as43pq ,
EN300-21650
nsc 521752
einecs 213-745-3
methoxy-5 indole [french]
indol-5-yl methyl ether
AB-337/25021007
inchi=1/c9h9no/c1-11-8-2-3-9-7(6-8)4-5-10-9/h2-6,10h,1h
1h-indole, 5-methoxy-
1006-94-6
5-methoxy-1h-indole
nsc-521752
5-methoxyindole
methoxy-5 indole
femedol
indole, 5-methoxy-
wln: t56 bmj go1
nsc521752
5-methoxyindole, 99%
M-3454
M-3456
bz3 ,
AC-10504
CHEMBL280311 ,
M0731
AKOS000121317
A18677
916979-77-6
1,3-dihydro-5-methyl-2h-indol-2-one
5-methoxy indole
STK510267
bdbm50400288
BP-10264
AB00488
3IMG
AM671
FT-0620569
SCHEMBL74720
3IMC
CG-0503
5-(methyloxy)-1h-indole
5-methoxy-indole
5-methoxyindol
5methoxyindole
1h-indol-5-yl methyl ether #
STR01848
mfcd00005674
DTXSID80143424
CS-W007328
5-methyoxyindole
BCP26682
ethyl7,8-dichloro-1,4-dihydro-4-oxoquinoline-3-carboxylate
SY004368
Q27276543
CHEBI:167807
PB39301
1h-indol-5-yl methyl ether
HY-W007328
Z104507276
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
indolesAny compound containing an indole skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Pantothenate synthetaseMycobacterium tuberculosisKd1,100.00001,100.00001,100.00001,100.0000AID977611
Chain A, Pantothenate synthetaseMycobacterium tuberculosisKd1,100.00001,100.00001,100.00001,100.0000AID977611
Chain A, Pantothenate synthetaseMycobacterium tuberculosisKd1,100.00001,100.00001,100.00001,100.0000AID977611
Chain A, Pantothenate synthetaseMycobacterium tuberculosisKd1,100.00001,100.00001,100.00001,100.0000AID977611
Chain A, Pantothenate synthetaseMycobacterium tuberculosisKd1,100.00001,100.00001,100.00001,100.0000AID977611
Chain A, Pantothenate synthetaseMycobacterium tuberculosisKd1,100.00001,100.00001,100.00001,100.0000AID977611
Chain B, Pantothenate synthetaseMycobacterium tuberculosisKd1,100.00001,100.00001,100.00001,100.0000AID977611
Chain A, Pantothenate synthetaseMycobacterium tuberculosisKd1,100.00001,100.00001,100.00001,100.0000AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1530048Inhibition of Streptococcus pyogenes SrtA deltaN81 mutant expressed in Escherichia coli BL21(DE3) at 100 uM using Abz-LPETA-Dap(Dnp) as substrate preincubated for 10 mins followed by substrate addition measured every min for 2.5 hrs by fluorimetric assay 2019European journal of medicinal chemistry, Jan-01, Volume: 161Identification of potential antivirulence agents by substitution-oriented screening for inhibitors of Streptococcus pyogenes sortase A.
AID125790Apparent inhibitory constant (Ki) for Bufuralol 1'-hydroxylation by human liver microsomes; Non-competitive inhibition1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies.
AID73213Residual porcine GSK-3-alpha/beta kinase activity with L240C/N297Q mutant cytochrome P450 2A6 extract2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Generation of new protein kinase inhibitors utilizing cytochrome p450 mutant enzymes for indigoid synthesis.
AID763540Antioxidant activity assessed as inhibition of ABTS free radical generation at 33 uM after 20 mins by UV spectrophotometric analysis relative to control2013Bioorganic & medicinal chemistry, Aug-01, Volume: 21, Issue:15
Indole derivatives as dual-effective agents for the treatment of neurodegenerative diseases: synthesis, biological evaluation, and molecular modeling studies.
AID54183Residual Cyclin-dependent kinase 5-p35nck5a activity with L240C-mutant cytochrome P450 2A6 extract2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Generation of new protein kinase inhibitors utilizing cytochrome p450 mutant enzymes for indigoid synthesis.
AID54188Residual Cyclin-dependent kinase 5-p35nck5a activity with L240C/N297Q mutant cytochrome P450 2A6 extract2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Generation of new protein kinase inhibitors utilizing cytochrome p450 mutant enzymes for indigoid synthesis.
AID763541Antioxidant activity assessed as inhibition of ABTS free radical generation at 9 uM after 20 mins by UV spectrophotometric analysis relative to control2013Bioorganic & medicinal chemistry, Aug-01, Volume: 21, Issue:15
Indole derivatives as dual-effective agents for the treatment of neurodegenerative diseases: synthesis, biological evaluation, and molecular modeling studies.
AID73208Residual porcine GSK-3-alpha/beta kinase activity with L240C mutant cytochrome P450 2A6 extract2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Generation of new protein kinase inhibitors utilizing cytochrome p450 mutant enzymes for indigoid synthesis.
AID763542Antioxidant activity assessed as inhibition of ABTS free radical generation at 17 uM after 20 mins by UV spectrophotometric analysis relative to control2013Bioorganic & medicinal chemistry, Aug-01, Volume: 21, Issue:15
Indole derivatives as dual-effective agents for the treatment of neurodegenerative diseases: synthesis, biological evaluation, and molecular modeling studies.
AID656681Inhibition of electric eel AChE using acetylcholine iodide as substrate at 10'-4 M measured every 5 sec for 2 mins by Ellman's method2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Prospective acetylcholinesterase inhibitory activity of indole and its analogs.
AID704839Binding affinity to Mycobacterium tuberculosis Pantothenate synthetase ATP-binding site by ITC method2011Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4
ATP-binding site of bacterial enzymes as a target for antibacterial drug design.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2011Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4
ATP-binding site of bacterial enzymes as a target for antibacterial drug design.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2009Angewandte Chemie (International ed. in English), , Volume: 48, Issue:45
Application of fragment growing and fragment linking to the discovery of inhibitors of Mycobacterium tuberculosis pantothenate synthetase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (9.52)18.7374
1990's1 (4.76)18.2507
2000's4 (19.05)29.6817
2010's12 (57.14)24.3611
2020's2 (9.52)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.18 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index5.20 (4.65)
Search Engine Demand Index42.91 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (35.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (9.52%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (90.48%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]